Lilly Does Not Expect A Quick Medicare Coverage Decision For Donanemab
Eisai Will Make A Case For Lecanemab Soon
Donanemab may receive accelerated approval for Alzheimer’s disease in early 2023, but Lilly will not approach CMS about Medicare coverage until mid-year when it has Phase III data – and even then does not expect a quick decision.
